Fotemustine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Fotemustine
Fotemustine.svg
Clinical data
Trade names Mustophoran
AHFS/Drugs.com International Drug Names
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard 100.158.792
Chemical and physical data
Formula C9H19ClN3O5P
Molar mass 315.691 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Fotemustine is a nitrosourea alkylating agent approved for use in the treatment of metastasising melanoma. A study[1] has shown that fotemustine produces improved response rates and but does not increase survival (over dacarbazine in the treatment of disseminated cutaneous melanoma. Median survival was 7.3 months with fotemustine versus 5.6 months with DTIC (P=.067). There was also toxicity prevalence in fotemustine arm. The main toxicity was grade 3 to 4 neutropenia (51% with fotemustine v 5% with DTIC) and thrombocytopenia (43% v 6%, respectively).

External links[edit]

  1. ^ Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M (March 2004). "Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study". 22 (6): 1118–25. doi:10.1200/JCO.2004.04.165. PMID 15020614.